International Outsourcing of Medical Research by High-Income Countries: Changes from 1995 to 2005

Abstract

Background

Medical research outsourcing provides a financial benefit to those conducting research and financial incentives to the developing countries hosting the research. Little is known about how frequently outsourcing occurs or the type of research that is outsourced.

Methods

To document changes in medical research outsourcing over a 10-year period, we conducted a cross-sectional comparison of 3 medical journals: Lancet, The New England Journal of Medicine, and JAMA: The Journal of the American Medical Association in the last 6 months of 1995 and 2005. The main outcome measure was the 10-year change in proportion of studies including patients from low-income countries.

Findings

We reviewed 598 articles. During the 10-year period, the proportion of first authors from low-income countries increased from 3% to 6% (P = 0.21), whereas studies with participants from low-income countries increased from 8% to 22% (P = < 0.001). In 2005, compared with studies conducted exclusively in high-income countries, those including participants from low-income countries were more likely to be randomized trials (55% vs 35%, P = 0.004), to study medications (65% vs 34%, P < 0.001), to be funded by pharmaceutical companies (33% vs 21%, P = 0.05), and to involve pediatric populations (29% vs 8%, P < 0.001).

Interpretation

Outsourcing of medical research seems to be increasing. Additional studies are required to know if subjects from low-income countries are being adequately protected.

Keywords

outsourcing medical research

Get full access to this article

View all access options for this article.

References

Overby

ABC: an introduction to outsourcing. Available at: http://www.cio.com/article/40380/ABC_An_Introduction_to_Outsourcing/1. Accessed July 7, 2008.

Wachter

RM.

The “dis-location” of U.S. medicine-the implications of medical outsourcing. N Engl J Med. 2006;354:661–665.

Gross

, Weintraub

Outsourcing medical products to Asia. Pacific Bridge Medical. Available at: http://www.pacificbridgemedical.com/publications/html/AsiaAug2005.htm. Accessed July 7,2008.

Maiti

R M R.

Clinical trials in India. Pharmacol Res. 2007;56:1–10.

Srinivasan

Indian guinea pigs for sale: outsourcing clinical trials. India Resource Center. Available at: http://www.indiaresource.org/issues/globalization/2004/indianguineapigs.html. Accessed November 30, 2009.

Glickman

, McHutchison

, Peterson

, . Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360:816–823.

Brower

Going global in R&D. EMBO Rep. 2004;5:333–335.

Thiers

, Sinskey

, Berndt

Trends in the globalization of clinical trials. Nat Rev Drug Discov. 2008;7:13–14.

Ortiz

. Paid studies draw more interest in sour economy. Boston Globe. 2009 Available at: http://www.boston.com/news/world/europe/articles/2009/01/05/paid_studies_draw_more_interest_in_sour_economy/. Accessed November 30, 2009.

10.

Elliott

, Abadie

Exploiting a research underclass in phase 1 clinical trials. N Engl J Med. 2008;358:2316–2317.

11.

Hyder

, Wali

, Khan

, . Ethical review of health research: a perspective from developing country researchers. J Med Ethics. 2004;30:68–72.

12.

Robison

VA.

Some ethical issues in international collaborative research in developing countries. Int Dent J. 1998;48:552–556.

13.

Raja

AJ.

The revised Helsinki Declaration: is it enough?

Issues Med Ethics. 2001;9:114–116.

14.

Akst

. On the contrary: Nike in Indonesia, through a different lens. New York Times, 2001. Available at: http://www.nytimes.com/2001/03/04/business/on-the-contrary-nike-in-indonesia-through-a-different-lens.html. Accessed November 30, 2009.

15.

Office of the Inspector General . The Food and Drug Administration's Oversight of Clinical Trials. Washington, DC: Department of Health and Human Services; 2007.